These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 24106335)
1. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Sommer IE; van Westrhenen R; Begemann MJ; de Witte LD; Leucht S; Kahn RS Schizophr Bull; 2014 Jan; 40(1):181-91. PubMed ID: 24106335 [TBL] [Abstract][Full Text] [Related]
2. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Çakici N; van Beveren NJM; Judge-Hundal G; Koola MM; Sommer IEC Psychol Med; 2019 Oct; 49(14):2307-2319. PubMed ID: 31439071 [TBL] [Abstract][Full Text] [Related]
3. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. Sommer IE; de Witte L; Begemann M; Kahn RS J Clin Psychiatry; 2012 Apr; 73(4):414-9. PubMed ID: 22225599 [TBL] [Abstract][Full Text] [Related]
4. Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Cho M; Lee TY; Kwak YB; Yoon YB; Kim M; Kwon JS Aust N Z J Psychiatry; 2019 Aug; 53(8):742-759. PubMed ID: 30864461 [TBL] [Abstract][Full Text] [Related]
5. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. Pawełczyk T; Grancow-Grabka M; Kotlicka-Antczak M; Trafalska E; Pawełczyk A J Psychiatr Res; 2016 Feb; 73():34-44. PubMed ID: 26679763 [TBL] [Abstract][Full Text] [Related]
6. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193 [TBL] [Abstract][Full Text] [Related]
7. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia. Koola MM Asian J Psychiatr; 2019 Feb; 40():100-102. PubMed ID: 30776665 [TBL] [Abstract][Full Text] [Related]
9. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Nitta M; Kishimoto T; Müller N; Weiser M; Davidson M; Kane JM; Correll CU Schizophr Bull; 2013 Nov; 39(6):1230-41. PubMed ID: 23720576 [TBL] [Abstract][Full Text] [Related]
10. A review of anti-inflammatory agents for symptoms of schizophrenia. Keller WR; Kum LM; Wehring HJ; Koola MM; Buchanan RW; Kelly DL J Psychopharmacol; 2013 Apr; 27(4):337-42. PubMed ID: 23151612 [TBL] [Abstract][Full Text] [Related]
11. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Breier A; Liffick E; Hummer TA; Vohs JL; Yang Z; Mehdiyoun NF; Visco AC; Metzler E; Zhang Y; Francis MM Schizophr Res; 2018 Sep; 199():395-402. PubMed ID: 29588126 [TBL] [Abstract][Full Text] [Related]
14. Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials. Arteaga-Henríquez G; Gisbert L; Ramos-Quiroga JA CNS Drugs; 2023 Mar; 37(3):215-229. PubMed ID: 36913130 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - A comprehensive systematic review and meta-analysis. Jeppesen R; Christensen RHB; Pedersen EMJ; Nordentoft M; Hjorthøj C; Köhler-Forsberg O; Benros ME Brain Behav Immun; 2020 Nov; 90():364-380. PubMed ID: 32890697 [TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233 [TBL] [Abstract][Full Text] [Related]
17. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression. Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489 [TBL] [Abstract][Full Text] [Related]